1.Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. British Journal Of Cancer. 2004 06/08/online;91:355.
2.Poduri A, Evrony GD, Cai X, Walsh CA. Somatic mutation, genomic variation, and neurological disease. Science (New York, NY). 2013;341(6141):1237758-. PubMed PMID: 23828942.
3.Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017 04/26/online;545:446.
4.de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science. 2014 Oct 10;346(6206):251–6. PubMed PMID: 25301630. Pubmed Central PMCID: PMC4636050.
5.Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nature communications. 2016;7:11815.
6.Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. Journal of clinical oncology. 2008;26(15):2442–9.
7.Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M. Nature medicine. 2015;21(6):560.
8.Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013 Mar;31(3):213–9. PubMed PMID: 23396013. Pubmed Central PMCID: PMC3833702.
9.Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012 Mar;22(3):568–76. PubMed PMID: 22300766. Pubmed Central PMCID: PMC3290792.
10.Kockan C, Hach F, Sarrafi I, Bell RH, McConeghy B, Beja K, et al. SiNVICT: ultra-sensitive detection of single nucleotide variants and indels in circulating tumour DNA. Bioinformatics. 2017 Jan 1;33(1):26–34. PubMed PMID: 27531099.
11.Lai Z, Markovets A, Ahdesmaki M, Chapman B, Hofmann O, McEwen R, et al. VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic Acids Res. 2016 Jun 20;44(11):e108. PubMed PMID: 27060149. Pubmed Central PMCID: PMC4914105.
12.McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010 Sep;20(9):1297–303. PubMed PMID: 20644199. Pubmed Central PMCID: PMC2928508.
13.Xu H, DiCarlo J, Satya RV, Peng Q, Wang Y. Comparison of somatic mutation calling methods in amplicon and whole exome sequence data. BMC genomics. 2014;15(1):244.
14.Sandmann S, De Graaf AO, Karimi M, Van Der Reijden BA, Hellström-Lindberg E, Jansen JH, et al. Evaluating variant calling tools for non-matched next-generation sequencing data. Scientific reports. 2017;7:43169.
15.Spencer DH, Tyagi M, Vallania F, Bredemeyer AJ, Pfeifer JD, Mitra RD, et al. Performance of common analysis methods for detecting low-frequency single nucleotide variants in targeted next-generation sequence data. The Journal of Molecular Diagnostics. 2014;16(1):75–88.
16.Alioto TS, Buchhalter I, Derdak S, Hutter B, Eldridge MD, Hovig E, et al. A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing. Nature communications. 2015;6:10001.
17.Krøigård AB, Thomassen M, Lænkholm A-V, Kruse TA, Larsen MJ. Evaluation of nine somatic variant callers for detection of somatic mutations in exome and targeted deep sequencing data. PLoS One. 2016;11(3):e0151664.
18.Remon J, Soria JC, Planchard D, Jovelet C, Pannet C, Lacroix L, et al. Liquid biopsies for molecular profiling of mutations in non-small cell lung cancer patients lacking tissue samples. AACR; 2016.
19.Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature medicine. 2014;20(5):548.
20.Newman AM, Lovejoy AF, Klass DM, Kurtz DM, Chabon JJ, Scherer F, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nature biotechnology. 2016;34(5):547.
21.Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science. 2014 Oct 10;346(6206):256–9. PubMed PMID: 25301631. Pubmed Central PMCID: PMC4354858.
22.Schmitt MW, Fox EJ, Prindle MJ, Reid-Bayliss KS, True LD, Radich JP, et al. Sequencing small genomic targets with high efficiency and extreme accuracy. Nature methods. 2015;12(5):423.
23.Schmitt MW, Kennedy SR, Salk JJ, Fox EJ, Hiatt JB, Loeb LA. Detection of ultra-rare mutations by next-generation sequencing. Proceedings of the National Academy of Sciences. 2012;109(36):14508–13.
24.Shugay M, Zaretsky AR, Shagin DA, Shagina IA, Volchenkov IA, Shelenkov AA, et al. MAGERI: Computational pipeline for molecular-barcoded targeted resequencing. PLoS computational biology. 2017;13(5):e1005480.
25.Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B. Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A. 2011 2011/06//;108(23):9530–5. PubMed PMID: 21586637. eng.
26.Fang LT, Afshar PT, Chhibber A, Mohiyuddin M, Fan Y, Mu JC, et al. An ensemble approach to accurately detect somatic mutations using SomaticSeq. Genome biology. 2015;16(1):197.
27.Peng Q, Satya RV, Lewis M, Randad P, Wang Y. Reducing amplification artifacts in high multiplex amplicon sequencing by using molecular barcodes. BMC genomics. 2015;16(1):589.
28.Lanman RB, Mortimer SA, Zill OA, Sebisanovic D, Lopez R, Blau S, et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PloS one. 2015;10(10):e0140712.
29.Schwarzenbach H, Müller V, Milde-Langosch K, Steinbach B, Pantel K. Evaluation of cell-free tumour DNA and RNA in patients with breast cancer and benign breast disease. Molecular BioSystems. 2011;7(10):2848–54.
30.Park J-L, Kim HJ, Choi BY, Lee H-C, Jang H-R, Song KS, et al. Quantitative analysis of cell-free DNA in the plasma of gastric cancer patients. Oncol Lett. 2012 2012/04//;3(4):921–6. PubMed PMID: 22741019. eng.
31.Szpechcinski A, Chorostowska-Wynimko J, Struniawski R, Kupis W, Rudzinski P, Langfort R, et al. Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease. British journal of cancer. 2015;113(3):476–83. PubMed PMID: 26125447. Epub 06/30.
32.Schwarzenbach H, Stoehlmacher J, Pantel K, Goekkurt E. Detection and Monitoring of Cell-Free DNA in Blood of Patients with Colorectal Cancer. Annals of the New York Academy of Sciences. 2008;1137(1):190–6.
33.Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nature Medicine. 2018 2018/09/01;24(9):1441–8.
34.Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome medicine. 2017;9(1):34-. PubMed PMID: 28420421.
35.Benayed R, Offin M, Mullaney K, Sukhadia P, Rios K, Desmeules P, et al. High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden. Clinical Cancer Research. 2019;25(15):4712–22.
36.Deng S, Lira M, Huang D, Wang K, Valdez C, Kinong J, et al. TNER: a novel background error suppression method for mutation detection in circulating tumor DNA. BMC Bioinformatics. 2018 2018/10/20;19(1):387.
37.Costello M, Pugh TJ, Fennell TJ, Stewart C, Lichtenstein L, Meldrim JC, et al. Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation. Nucleic acids research. 2013;41(6):e67-e.
38.Shagin DA, Shagina IA, Zaretsky AR, Barsova EV, Kelmanson IV, Lukyanov S, et al. A high-throughput assay for quantitative measurement of PCR errors. Scientific Reports. 2017 2017/06/02;7(1):2718.
39.Kebschull JM, Zador AM. Sources of PCR-induced distortions in high-throughput sequencing data sets. Nucleic acids research. 2015;43(21):e143-e.
40.Deng Q, Xie B, Wu L, Ji X, Li C, Feng L, et al. Competitive evolution of NSCLC tumor clones and the drug resistance mechanism of first-generation EGFR-TKIs in Chinese NSCLC patients. Heliyon. 2018;4(12):e01031.
41.Li H. Toward better understanding of artifacts in variant calling from high-coverage samples. Bioinformatics. 2014;30(20):2843–51.
42.Gymrek M, Golan D, Rosset S, Erlich Y. lobSTR: A short tandem repeat profiler for personal genomes. Genome research. 2012 2012/06//;22(6):1154–62. PubMed PMID: 22522390. eng.
43.Sinha R, Stanley G, Gulati GS, Ezran C, Travaglini KJ, Wei E, et al. Index switching causes “spreading-of-signal” among multiplexed samples in Illumina HiSeq 4000 DNA sequencing. BioRxiv. 2017:125724.
44.Mouliere F, Chandrananda D, Piskorz AM, Moore EK, Morris J, Ahlborn LB, et al. Enhanced detection of circulating tumor DNA by fragment size analysis. Science Translational Medicine. 2018;10(466):eaat4921.
45.Cristiano S, Leal A, Phallen J, Fiksel J, Adleff V, Bruhm DC, et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature. 2019 2019/06/01;570(7761):385–9.
46.Mouliere F, Mair R, Chandrananda D, Marass F, Smith CG, Su J, et al. Detection of cell‐free DNA fragmentation and copy number alterations in cerebrospinal fluid from glioma patients. EMBO Molecular Medicine. 2018:e9323.
47.Barnell EK, Ronning P, Campbell KM, Krysiak K, Ainscough BJ, Sheta LM, et al. Standard operating procedure for somatic variant refinement of sequencing data with paired tumor and normal samples. Genetics in Medicine. 2019 2019/04/01;21(4):972–81.